Jefferies Global Healthcare Conference
Logotype for Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals (LXRX) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Lexicon Pharmaceuticals Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

Pipeline and catalysts

  • Strategic focus on serious cardiometabolic disease, with late- and early-stage programs advancing across the pipeline.

  • Sotagliflozin’s phase III SONATA trial in HCM is fully enrolled, with a Q1 2027 readout; type 1 diabetes NDA resubmission is planned for Q1 2027, with potential approval in 2027.

  • AAK1 diabetic peripheral neuropathy program is phase III-ready; work continues across additional AAK1 indications, while Novo Nordisk-partnered LX9851 is in obesity and other indications.

SONATA and HCM opportunity

  • SONATA enrolled 542 patients: 440 non-obstructive and 102 obstructive; about 40 patients were taking a cardiac myosin inhibitor at entry.

  • Primary endpoint is KCCQ change at week 24 across obstructive and non-obstructive HCM; the study was powered for an approximately five-point placebo-adjusted difference.

  • Management expects a similar KCCQ effect across both subgroups, citing sotagliflozin’s proposed diastolic effects; it highlighted substantial unmet need in non-obstructive HCM.

  • Rationale includes dual SGLT1/2 activity, myocardial SGLT1 expression, effects on thromboembolic mechanisms, and cardiorenal benefits; management characterized the medicine as once-daily, oral, safe and tolerable.

  • Q1 topline is expected to include the primary endpoint across the combined population and safety details; most secondary endpoints are planned for a later medical meeting.

Type 1 diabetes and safety

  • FDA discussions aligned on at least 200 patient-years of exposure and a DKA rate below the inTandem program’s ~3.5 cases per 100 patient-years.

  • STENO1 data through end-August met both criteria, with 200 patient-years of exposure and ~1 DKA case per 100 patient-years, similar to untreated controls and below inTandem; enrollment continues.

  • Management said the additional safety criteria were met and the resubmission file is being prepared; sotagliflozin could be the first and only adjunct to insulin for type 1 diabetes.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Lexicon Pharmaceuticals